Renal Agents
Vasopressin regulates apical targeting of aquaporin-2 but not of UT1 urea transporter in renal collecting duct. (1/159)
In the renal inner medullary collecting duct (IMCD), vasopressin regulates two key transporters, namely aquaporin-2 (AQP2) and the vasopressin-regulated urea transporter (VRUT). Both are present in intracellular vesicles as well as the apical plasma membrane. Short-term regulation of AQP2 has been demonstrated to occur by vasopressin-induced trafficking of AQP2-containing vesicles to the apical plasma membrane. Here, we have carried out studies to determine whether short-term regulation of VRUT occurs by a similar process. Cell surface labeling with NHS-LC-biotin in rat IMCD suspensions revealed that vasopressin causes a dose-dependent increase in the amount of AQP2 labeled at the cell surface, whereas VRUT labeled at the cell surface did not increase in response to vasopressin. Immunoperoxidase labeling of inner medullary thin sections from Brattleboro rats treated with 1-desamino-8-D-arginine vasopressin (DDAVP) for 20 min revealed dramatic translocation of AQP2 to the apical region of the cell, with no change in the cellular distribution of VRUT. In addition, differential centrifugation of inner medullary homogenates from Brattleboro rats treated with DDAVP for 60 min revealed a marked depletion of AQP2 from the low-density membrane fraction (enriched in intracellular vesicles) but did not alter the quantity of VRUT in this fraction. Finally, AQP2-containing vesicles immunoisolated from a low-density membrane fraction from renal inner medulla did not contain immunoreactive VRUT. Thus vasopressin-mediated regulation of AQP2, but not of VRUT, depends on regulated vesicular trafficking to the plasma membrane. (+info)Plasma vasopressin and response to treatment in primary nocturnal enuresis. (2/159)
AIMS: To examine the relation between nocturnal vasopressin release and response to treatment with the vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVP) in children with primary monosymptomatic nocturnal enuresis. DESIGN: Children were recruited from a specific enuresis clinic and entered into a defined treatment programme. Nocturnal vasopressin concentrations were measured every 15 minutes over a four hour period during overnight admission. RESULTS: Sixty seven children were eligible for entry into the study, 35 of whom agreed to overnight sampling. There was a quadratic relation between mean plasma AVP and response to treatment with DDAVP, with very high or very low concentrations being unresponsive. Plasma AVP profiles ranged from low concentrations with little variability to high concentrations with wide variability. CONCLUSION: The ability to respond to DDAVP is related to endogenous AVP production and is influenced by neuronal patterning in early infancy. The best predictors of success with treatment were a past history of breast feeding, mean nocturnal AVP concentration, and the height of the child. The response was adversely affected by poor weight at birth and poor linear growth. The study suggests differing causes of nocturnal enuresis related to different patterns of AVP release. (+info)Active lucifer yellow secretion in renal proximal tubule: evidence for organic anion transport system crossover. (3/159)
Recent studies show that organic anion secretion in renal proximal tubule is mediated by distinct sodium-dependent and sodium-independent transport systems. Here we investigated the possibility that organic anions entering the cells on one system can exit into the lumen on a transporter associated with the other system. In isolated rat kidneys perfused with 10 microM lucifer yellow (LY, a fluorescent organic anion) plus 100 micrograms/ml inulin, the LY-to-inulin clearance ratio averaged 1.6 +/- 0.2, indicating net tubular secretion. Probenecid significantly reduced both LY clearance and LY accumulation in kidney tissue. In intact killifish proximal tubules, confocal microscopy was used to measure steady-state LY uptake into cells and secretion into the tubular lumen. Probenecid, p-aminohippurate, and ouabain nearly abolished both uptake and secretion. To this point, the data indicated that LY was handled by the sodium-dependent and ouabain-sensitive organic anion transport system. However, leukotriene C4, an inhibitor of the luminal step for the sodium-independent and ouabain-insensitive organic anion system, reduced luminal secretion of LY by 50%. Leukotriene C4 did not affect cellular accumulation of LY or the transport of fluorescein on the sodium-dependent system. A similar inhibition pattern was found for another fluorescent organic anion, a mercapturic acid derivative of monochlorobimane. Thus, both organic anions entered the cells on the basolateral transporter for the classical, sodium-dependent system, but about half of the transport into the lumen was handled by the luminal carrier for the sodium-independent system, which is most likely the multidrug resistance-associated protein. This is the first demonstration that xenobiotics can enter renal proximal tubule cells on the carrier associated with one organic anion transport system and exit into the tubular lumen on multiple carriers, one of which is associated with a second system. (+info)Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis. (4/159)
The case of a 6 year old child who presented with convulsions and coma after unsupervised self administration of intranasal desmopressin (DDAVP) for nocturnal enuresis is presented. Children with enuresis can be embarassed by their condition and may believe that multiple doses of their nasal spray may bring about a rapid resolution. Water intoxication is an uncommon but serious adverse effect of treatment with intranasal DDAVP. These patients may present with seizure, mental state changes, or both. Basic management consists of stopping the drug, fluid restriction, and suppressive treatment for seizures. Recovery is usually rapid and complete. Administration of the nasal spray in children should be supervised by parents to prevent highly motivated children from accidental overdose. The risks of high fluid intake need to be carefully explained to both parents and children. (+info)Effect of DDAVP on nocturnal enuresis in a patient with nephrogenic diabetes insipidus. (5/159)
The case of an 8 year old boy with both nocturnal enuresis and nephrogenic diabetes insipidus is presented. Diagnosis of nephrogenic diabetes insipidus was based on a typical medical history, the characteristic result of a fluid restriction test, the lack of an effect of 1-desamino-8-D-arginine (DDAVP) on both urine osmolality and plasma coagulation factors and, finally, the detection of a hemizygous missense mutation within the arginine vasopressin (AVP) receptor gene. Hydrochlorothiazide treatment and dietary measures reduced the patient's urine volume to one third of its original volume. However, this had no effect on enuresis. The daily intranasal application of DDAVP did not further reduce urine output but dramatically decreased the frequency of bed wetting. This observation contradicts the common notion that the therapeutic effect of DDAVP in nocturnal enuresis is the result of compensation for a nocturnal AVP deficit. Rather, it points to a different mode of action of DDAVP in patients with enuresis. It is hypothesised that central AVP receptors are a target of DDAVP and that they might play an important role in the pathogenesis of nocturnal enuresis. (+info)Transport of [3H]losartan across isolated perfused rabbit proximal tubule. (6/159)
The transport of the angiotensin II receptor antagonist losartan and its interaction with organic anion transport were examined in the isolated perfused rabbit proximal tubule. Losartan reversibly inhibited the secretion of para-aminohippurate (PAH) in a concentration-dependent manner (IC50 = 15 +/- 0.5 microM). Other angiotensin II receptor antagonists also inhibited PAH secretion with similar potencies: eprosartan, 11 +/- 2.3 microM; irbesartan, 17 +/- 2.2 microM; and valsartan 3 +/- 0.6 microM. [3H]Losartan was secreted by the proximal tubule by a saturable and probenecid-sensitive mechanism. The affinity of losartan for the organic anion transporter (Km = 12.3 +/-1.8 microM) was significantly greater than that of PAH (Km = 88.5 +/- 10.7 microM). [3H]Losartan secretion was stimulated in the presence of alpha-ketoglutarate, suggesting that losartan, like PAH, enters the cell in exchange for a dicarboxylate. These results demonstrate that losartan and probably other nonpeptide angiotensin II receptor antagonists are secreted by an organic anion transporter that is similar to, if not identical with, the classic PAH transporter. (+info)Hypercalcemia accompanied by hypothalamic hypopituitarism, central diabetes inspidus and hyperthyroidism. (7/159)
We present here a case of prominent hypercalcemia accompanied by hypothalamic tumor and Graves' disease. A 24-year-old man with hypothalamic tumor showed hypopituitarism, central diabetes inspidus (DI) and hyperthyroidism. Nausea, loss of thirst and appetite, and general fatigue were found with the unveiling of hypercalcemia and hypernatremia. Parathyroid hormone (PTH) and 1alpha-dihydroxyvitamin D levels were suppressed with a normal range of PTH-related protein values. One-desamino-(8-D-arginine)-vasopressin (DDAVP) and half-saline administration normalized hypernatremia, while hypercalcemia was still sustained. Administration of cortisone acetate and thiamazole reduced the elevated serum Ca level. In the present case, concurrent hyperthyroidism was assumed to accelerate skeletal mobilization of calcium into the circulation. Hypocortisolism and central DI was also considered to contribute, to some extent, to the hypercalcemia through renal handling of Ca. (+info)Lack of vasopressin-independent upregulation of AQP-2 gene expression in homozygous Brattleboro rats. (8/159)
Arginine vasopressin (AVP) plays an important role in the expression of aquaporin (AQP-2) in the collecting duct. The present study was undertaken to determine whether there is an AVP-independent regulation of AQP-2 gene expression in homozygous Brattleboro rats in which endogenous AVP is absent. Exogenous administration of 1-deamino-8-D-AVP produced an antidiuresis and expressed AQP-2 mRNA and AQP-2 protein in the renal medulla of the homozygous Brattleboro rats. Twelve hours of water deprivation produced severe dehydration in the homozygous Brattleboro rats, such that urinary osmolality increased from 200 to 649 mosmol/kgH(2)O. However, no increase in AQP-2 mRNA expression was observed after this dehydration, and the medullary tissue content and urinary excretion of AQP-2 also remained unchanged. Increases in AQP-2 mRNA expression and AQP-2 protein were evident in Long-Evans rats after 64 h of water deprivation, with a severity of dehydration almost equal to the 12-h dehydrated, homozygous Brattleboro rats. These results indicate the lack of an AVP-independent mechanism for upregulating AQP-2 mRNA expression in renal collecting duct cells. (+info)"Renal agents" is not a standardized medical term with a single, widely accepted definition. However, in a general sense, renal agents could refer to medications or substances that have an effect on the kidneys or renal function. This can include drugs that are primarily used to treat kidney diseases or disorders (such as certain types of diuretics, ACE inhibitors, or ARBs), as well as chemicals or toxins that can negatively impact renal function if they are not properly eliminated from the body.
It's worth noting that the term "renal agent" is not commonly used in medical literature or clinical practice, and its meaning may vary depending on the context in which it is used. If you have any specific questions about a particular medication or substance and its effect on renal function, I would recommend consulting with a healthcare professional for more accurate information.
No data available that match "renal agents"
Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents
New Research Shows Viability of PET Imaging Agent for Clear Cell Renal Cell Carcinoma
Managing Renal Impairment with Multiple Agents
Metastatic renal cell carcinoma agent nearly doubles survival
Novel Agent N-803 Safe, Effective for BCG-Unresponsive High-Risk NMIBC - Renal and Urology News
Spectral imaging of microvascular function in a renal cell carcinoma after treatment with a vascular disrupting agent | (2009) ...
Wuzhi Tablet (Schisandra sphenanthera Extract) Is a Promising Tacrolimus-Sparing Agent for Renal Transplant Recipients Who Are...
EMF-Portal | A novel antioxidant agent caffeic acid phenethyl ester prevents long-term mobile phone exposure-induced renal...
Thrombolytic Therapy: Background, Thrombolytic Agents, Thrombolytic Therapy for Acute Myocardial Infarction
Heart Failure Medication: Beta-Blockers, Alpha Activity, Beta-Blockers, Beta-1 Selective, ACE Inhibitors, ARBs, Inotropic...
Chapter 3 Antiepileptic Agents in: Demystifying Drug Dosing in Renal Dysfunction
Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine - Fingerprint - Okayama University
the following are true of renal scintigraphy agents-UKMLA PLAB AMC USMLE Prometric MCQ
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. - Department of Oncology
Clinical Considerations for Treatment and Prophylaxis of Mpox Infection in People Who are Immunocompromised| Mpox | Poxvirus |...
N-Acetyl Cysteine (NAC): MedlinePlus Supplements
Ornipressin - Wikipedia
Part 09: Drugs Acting on the Renal System - Karch's Focus on Nursing Pharmacology, 9th Ed., Tucker - Chapter 51: Diuretic...
Hepatic dysfunction and/or renal impairments in older adults may limit the use of many glucose-lowering agents - Synthesis and...
Advanced Search Results - Public Health Image Library(PHIL)
HDCN -- ASN Renal Week 2005 Downloadable audiofiles
Updated MIMS table helps prescribers adjust doses of diabetes combination products | MIMS online
2020-2021 BCSC Basic and Clinical Science Course™
Blister Agents: Lewisite (L), Mustard-Lewisite Mixture (HL) | Medical Management Guidelines | Toxic Substance Portal | ATSDR
Profile | University of Otago
PROBENECID
Advanced Renal Cell Carc2
- The ongoing phase III ADAPT (The Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma) study is using this approach to personalized immunotherapy, with the goal of randomizing 450 patients. (urologytimes.com)
- CAMBRIDGE, Mass.--( BUSINESS WIRE )--AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). (businesswire.com)
Insufficiency5
- Injections of radiocontrast agents are a frequent cause of acute decreases in renal function, occurring most often in patients with chronic renal insufficiency and diabetes mellitus. (nih.gov)
- We prospectively studied 78 patients with chronic renal insufficiency (mean [+/- SD] serum creatinine concentration, 2.1 +/- 0.6 mg per deciliter [186 +/- 53 mumol per liter]) who underwent cardiac angiography. (nih.gov)
- In patients with chronic renal insufficiency who are undergoing cardiac angiography, hydration with 0.45 percent saline provides better protection against acute decreases in renal function induced by radiocontrast agents than does hydration with 0.45 percent saline plus mannitol or furosemide. (nih.gov)
- Obtain blood urea nitrogen (BUN) and creatinine levels to determine the presence of renal insufficiency, as serum magnesium levels rise when the creatinine clearance is less than 30 mL/min. (medscape.com)
- Probenecid may not be effective in chronic renal insufficiency particularly when the glomerular filtration rate is 30 mL/minute or less. (nih.gov)
Impairment5
- A novel antioxidant agent caffeic acid phenethyl ester prevents long-term mobile phone exposure-induced renal impairment in rat. (emf-portal.org)
- Dose adjustment is required for diabetes patients with renal impairment taking combination products containing metformin. (mims.co.uk)
- The guidance on metformin combination preparations reflects the recommended maximum daily metformin dose of 2g/day in patients with moderate renal impairment stage 3a (GFR 45-59ml/min) and 1g/day in patients with stage 3b (GFR 30-45ml/min). (mims.co.uk)
- Probenecid has been used in patients with some renal impairment, but dosage requirements may be increased. (nih.gov)
- Because of its mechanism of action, probenecid is not recommended in conjunction with a penicillin in the presence of known renal impairment. (nih.gov)
Dysfunction3
- However, CHCl3 produced a concentration-related dysfunction when added to renal cortical slices from Fischer 344 or Sprague-Dawley rats. (cdc.gov)
- Contrast agents should not be used in patients with renal dysfunction unless absolutely necessary. (medscape.com)
- and development of several imaging methods that could serve as noninvasive tools for renal and mitochondrial dysfunction, and several drug-companion biomarker pairs for sepsis associated AKI. (nih.gov)
Decrease in renal function2
- An acute radiocontrast-induced decrease in renal function was defined as an increase in the base-line serum creatinine concentration of at least 0.5 mg per deciliter (44 mumol per liter) within 48 hours after the injection of radiocontrast agents. (nih.gov)
- Acute Kidney Injury (AKI) Acute kidney injury is a rapid decrease in renal function over days to weeks, causing an accumulation of nitrogenous products in the blood (azotemia) with or without reduction in amount of urine. (msdmanuals.com)
Toxicity3
- Various ketonic agents potentiate the hepatic and renal toxicity of halogenated solvents in mice and rats. (cdc.gov)
- The degree of CHCl3 toxicity in vitro was not altered when renal cortical slices were preincubated with CHCl3 (8.5 microl) under an atmosphere of carbon monoxide. (cdc.gov)
- Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. (pediatriconcall.com)
Metastatic4
- A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study. (urologytimes.com)
- Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. (ox.ac.uk)
- This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
- Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
Hepatic2
Patients atteints3
- Nous avons enquêté auprès de 188 patients atteints d'une maladie rénale à l'aide de 36 questions à choix multiples dans deux hôpitaux des Émirats arabes unis. (who.int)
- RÉSUMÉ Une alimentation adaptée peut contribuer à lutter contre le syndrome cachectique chez les patients atteints d'une maladie rénale sous dialyse. (who.int)
- La présente étude d'intervention visait à identifier les problèmes de malnutrition et à évaluer l'effet de conseils diététiques sur l'amélioration de l'état de santé des patients atteints d'une maladie rénale en phase terminale soumis à une hémodialyse. (who.int)
Hypertension2
- If trials of antihypertensive drugs are any indication, the first results from randomized trials of renal denervation for resistant hypertension will show smaller reductions in blood pressure compared with those from the unblinded trials, a study in Heart indicated. (medpagetoday.com)
- In hypertension, it is used as an adjunct to prolonged therapy with thiazides and similar agents to prevent potassium depletion. (janusinfo.se)
Chronic kidney1
- Chronic Kidney Disease Chronic kidney disease (CKD) is long-standing, progressive deterioration of renal function. (msdmanuals.com)
Disease6
- These agents are also indicated to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus who with either established cardiovascular disease or multiple cardiovascular risk factors. (medscape.com)
- Outcome Measures in Renal Disease: How Good Are Surrogates? (hdcn.com)
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. (drugs.com)
- Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
- This intervention study aimed to identify malnutrition problems and assess the effect of dietary counselling on improvement of health status of end-stage renal disease patients subjected to haemodialysis. (who.int)
- Nutrition tips are tion of baseline data through inter- end-stage renal disease (ESRD) ranges another effective way of providing a views and laboratory reports with patients attending the centre to assess between 34 and 200 per million popula- practical nutrition education message their nutritional status. (who.int)
Pharmacology1
- It's exciting to work with this new imaging agent," noted Dr. Calais, an associate professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). (diagnosticimaging.com)
Acute kidney2
- As senior investigator and chief of the Renal Diagnostics and Therapeutics Unit, I lead a team that studies sepsis and acute kidney injury (AKI)-both are associated with high rates of illness and death. (nih.gov)
- 5. Lameire N., Kellum J. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2) // Critical Care. (medline.ru)
Intravascular1
- Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial //The Lancet. (medline.ru)
Diabetes1
- Diabetes Mellitus: To minimise the risk of hyperkalaemia in known or suspected diabetic patients, the status of renal function should be determined before initiating therapy. (janusinfo.se)
Tumor3
- We employed spectral imaging in a rodent window chamber model to observe and measure the oxygen transport function of tumor microvasculature in a human renal cell carcinoma after treatment with a fast acting vascular disrupting agent. (spie.org)
- Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. (harvard.edu)
- Tumor lysis syndrome: Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function ( 5.5 ). (drugs.com)
Glomerular1
- Although nonsteroidal anti-inflammatory drugs (NSAIDs) effectively treat a variety of inflammatory diseases, these agents may cause deleterious effects on kidney function, especially with respect to solute homeostasis and maintenance of renal perfusion and glomerular filtration. (nih.gov)
Angiography1
- An augmented patient-specific approach to administration of contrast agent for CT renal angiography. (harvard.edu)
Pulmonary Edema1
- These agents should not be used for myelography or in injections that may enter the spinal canal (because neurotoxicity is a risk) or the bronchial tree (because pulmonary edema is a risk). (msdmanuals.com)
Function3
- Drugs that selectively inhibit COX-2 might, therefore, be expected to produce effects on renal function similar to nonselective NSAIDs which inhibit both COX-1 and COX-2. (nih.gov)
- Also included are drugs used for their antidiuretic and uricosuric actions, for their effects on the kidneys' clearance of other drugs, and for diagnosis of renal function. (bvsalud.org)
- Contrast Nephropathy Contrast nephropathy is worsening of renal function after IV administration of radiocontrast and is usually temporary. (msdmanuals.com)
Kidney2
- A Simple Trick to Right Renal Vein Elongation in Deceased Donor Kidney Transplantation. (harvard.edu)
- A case of solitary kidney with duplex collecting systems and renal vascular variants in an adult male cadaver. (harvard.edu)
Refractory1
- Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. (drugs.com)
Heart failure2
- The rapid increase in extracellular volume and cardiac preload caused by hyperosmotic agents may precipitate or aggravate congestive heart failure. (aao.org)
- In congestive heart failure, Amiloride Hydrochloride may be effective alone, but its principal indication is for concomitant use in patients receiving thiazides or more potent diuretic agents. (janusinfo.se)
Vasoconstrictor1
- Ornipressin is a vasoconstrictor, haemostatic and renal agent. (wikipedia.org)
Osmotic agent1
- The osmotic agent enters the eye more rapidly when the blood-aqueous barrier is disrupted than when it is intact, reducing the effectiveness of the drug and its duration of action. (aao.org)
Diuretics1
- Of these 3 types of diuretics, loop diuretics have a greater effect on renal magnesium wasting because of their site of action. (medscape.com)
Inhibit1
- Probenecid also has been reported to inhibit the renal transport of many other compounds including aminohippuric acid (PAH), aminosalicylic acid (PAS), indomethacin, sodium iodomethamate and related iodinated organic acids, 17 -ketosteroids, pantothenic acid, phenolsulfonphthalein (PSP), sulfonamides, and sulfonylureas. (nih.gov)
MeSH1
- Renal Veins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
Dosage2
- Treatment should be started with a low dose of Amiloride, i.e. 5mg (1 tablet), plus a low dosage of the other diuretic agent. (janusinfo.se)
- If necessary, dosage of both agents may be increased gradually until there is effective diuresis. (janusinfo.se)
Cancer4
- Conventional imaging doesn't provide sufficient clarity for differentiating between benign renal masses and clear cell renal cell carcinoma (ccRCC), "the deadliest renal cancer and the most frequent one," noted Jeremie Calais, M.D, MSc, during an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago . (diagnosticimaging.com)
- The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. (diagnosticimaging.com)
- Final results from a pivotal clinical trial show that the investigational agent N-803 combined with bacillus Calmette-Guérin (BCG) is safe and more effective than other intravesical and systemic options for high-risk nonmuscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG alone, according to an oral presentation at the 2022 ASCO Annual Meeting. (renalandurologynews.com)
- While significant advances have been made in the treatment of renal cancer, there remains a need for effective yet more tolerable treatments, both for single agent and combination use," said Brian Rini, M.D., Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. (businesswire.com)
Inhibitors2
- I am pleased to see tivozanib return to the clinic, with the goal of better understanding its single agent potential through TIVO-3, and I look forward to realizing its potential for combination use with checkpoint inhibitors in future studies. (businesswire.com)
- It, therefore, seems unlikely that these COX-2 inhibitors (and perhaps their successors) will offer renal safety benefits over nonselective NSAID therapies, and, at this juncture, it is reasonable to assume that all NSAIDs, including COX-2-selective inhibitors, share a similar risk for adverse renal effects. (nih.gov)
Sensitivity1
- 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress. (diagnosticimaging.com)
Novel Agents1
- Trials for novel agents for the treatment of tuberculosis (TB) are under way. (medscape.com)
Tissues1
- Radiopaque contrast agents are often used in radiography and fluoroscopy to help delineate borders between tissues with similar radiodensity. (msdmanuals.com)
Adverse1
- Newer nonionic contrast agents are now routinely used at nearly all institutions because they have fewer adverse effects. (msdmanuals.com)
Adult1
- For the ZIRCON study, researchers assessed the use of 89 ZR-DFO-girentuximab (TLX250-CDx, Telix Pharmaceuticals) for ccRCC detection in adult patients with indeterminate renal masses. (diagnosticimaging.com)
Moderate1
- These agents have moderate afterload reduction properties and cause slight preload reduction. (medscape.com)
Injection1
- If contrast is necessary, a nonionic agent should be used, and patients should be premedicated with prednisone (50 mg orally 13 hours, 7 hours, and 1 hour before injection of contrast) and diphenhydramine (50 mg orally or IM 1 hour before the injection). (msdmanuals.com)
Glycerol1
- Common hyperosmotic agents include oral glycerol and intravenous mannitol. (aao.org)
Mild1
- In patients on probenecid who require a mild analgesic agent the use of acetaminophen rather than small doses of salicylates would be preferred. (nih.gov)
Trials4
- James Howard, MBBChir , of Imperial College London, and colleagues looked at the discrepancy between office-based and ambulatory readings in trials of antihypertensive agents and renal denervation. (medpagetoday.com)
- They included 31 drug trial with 4,121 patients and 23 renal denervation trials with 720 patients. (medpagetoday.com)
- There aren't any results from randomized, blinded trials for renal denervation yet, but in the unblinded trials, office-based systolic blood pressure drops averaged 27.6 mm Hg versus pretreatment values and 26.6 mm Hg versus untreated controls. (medpagetoday.com)
- Since Nocardia species infections are very often sporadic, information from randomized clinical trials comparing the clinical efficacy of specific antimicrobial agents is lacking. (antimicrobe.org)
Treatment3
- In addition, subdural and subarachnoid hemorrhages have been reported after treatment with hyperosmotic agents. (aao.org)
- The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma and other cancers. (businesswire.com)
- Treatment of monkeypox with tecovirimat as a first-line agent is available through CDC for compassionate use through an investigational drug protocol. (cdc.gov)
Tumour2
- The high vascularity and responsiveness to immunotherapy of renal cell carcinoma (RCC) makes such a tumour a potential target for IM862. (ox.ac.uk)
- For applications, including in the devel- but is required more simply to as- ease of reference, these five agents opment of human tumour profiles to sess the overall weight of the ev- are included in an expanded group assist in the identification of addition- idence in experimental animals. (who.int)
Acid1
- The association of 14CHCl3-derived radiolabel was increased over control by 2-hexanone pretreatment in protein, lipid, and acid soluble fractions from the renal cortex by approximately two-, two-, and fivefold, respectively. (cdc.gov)